BioSpace

FDA Action Alert: BMS, Bayer, Arrowhead and More

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...

Does Genmab’s Robust Q3 and Upbeat Outlook Reinforce the Bull Case for CPSE:GMAB?

In its most recent quarterly report, Genmab A/S posted strong results, with third quarter sales reaching US$1.02 billion and net income more than doubling compared to a year earlier. The company also ...
TipRanks on MSN

Genmab’s Earnings Call: Strong Growth Amid Challenges

Genmab (Otc) (($GMAB)) has held its Q3 earnings call. Read on for the main highlights of the call. Genmab’s recent earnings call painted a ...

Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (“Genmab”) announced on November 10, 2025, that it and its wholly owned subsidiary Genmab Finance LLC intend to offer, subject to market ...

Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday

HC Wainwright & Co. boosted the price target for Genmab A/S (NASDAQ: GMAB) from $40 to $41. HC Wainwright & Co. analyst ...

Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility

Media Release COPENHAGEN, Denmark; November 10, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) intend to offer, ...
Fintel on MSN

HC Wainwright & Co. Maintains Genmab A (GMAB) Buy Recommendation

Fintel reports that on November 10, 2025, HC Wainwright & Co. maintained coverage of Genmab A (NasdaqGS:GMAB) with a Buy recommendation. Analyst Price Forecast Suggests 117.15% Upside As of November 9 ...